# Paul Billings

> Paul R. Billings is an American physician-scientist, biotechnology executive, founder, and adviser whose career connects genomic research, public policy, clinical diagnostics, and company building. A Harvard-trained immunologist and clinical geneticist, he helped document genetic discrimination, worked on the policy debates that preceded federal protections, held academic appointments at Harvard, Stanford, UC San Francisco, and UC Berkeley, and later led or advised diagnostics businesses including GeneSage, Labcorp, Life Technologies, Natera, Biological Dynamics, Oncocyte, Fabric Genomics, and Longevity Life Advisors.

- **Role:** Consulting Chief Medical Officer at Oncocyte; Founder and Chief Medical Officer at Longevity Life Advisors; Scientific Advisory Board member at Lindus Health
- **Organizations:** Oncocyte, Longevity Life Advisors, Lindus Health, Biological Dynamics, Natera, Life Technologies, Thermo Fisher Scientific, Fabric Genomics, GeneSage, Cellective Dx, Labcorp, El Camino Hospital Genomic Medicine Institute, Cancer Commons, University of California, Berkeley, Stanford University, University of California, San Francisco, Harvard University
- **Nationality:** American
- **Education:** Undergraduate study, University of California, Santa Cruz, A.B., summa cum laude, University of California, San Diego, M.D., Harvard Medical School, Ph.D. in Immunology, Harvard University Graduate School of Arts and Sciences, Residency and fellowship training, University of Washington-affiliated hospitals
- **Known for:** Co-authored a landmark 1992 study that documented genetic discrimination and helped define the issue for policy debate., Contributed to public discussion and advisory work surrounding genetic privacy and nondiscrimination before passage of the Genetic Information Nondiscrimination Act of 2008., Received the James Tolbert Shipley Prize at Harvard Medical School for published research in 1979.

## Career timeline

- **1979** — Completed M.D. and Ph.D. degrees at Harvard; received Harvard Medical School's James Tolbert Shipley Prize for published research.
- **1979-1984** — Completed residency and medical-genetics fellowship training at University of Washington-affiliated hospitals, including work with Arno Motulsky.
- **1992** — Co-authored an American Journal of Human Genetics study documenting cases of genetic discrimination.
- **1990s-2000s** — Held clinical, academic, policy, and advisory positions spanning the VA, Stanford, UC Berkeley, UCSF, federal committees, and the Council for Responsible Genetics.
- **2003-2007** — Served in senior leadership at Labcorp, including corporate development and genetics/genomics responsibilities.
- **2010-2012** — Served as founding director and chief scientific officer of the Genomic Medicine Institute at El Camino Hospital.
- **2012** — Became Chief Medical Officer of Life Technologies.
- **2013-2016** — Continued as a consulting CMO within Thermo Fisher Scientific after its acquisition of Life Technologies.
- **2018-2022** — Served as Chief Medical Officer and Senior Vice President of Medical Affairs at Natera.
- **2022-2024** — Returned to Biological Dynamics as CEO and director, later described as chairman and CEO.
- **2025** — Appointed Consulting Chief Medical Officer of Oncocyte.
- **2026** — Joined the Scientific Advisory Board of Lindus Health; listed as founder and CMO of Longevity Life Advisors.

## Achievements

- Co-authored a landmark 1992 study that documented genetic discrimination and helped define the issue for policy debate.
- Contributed to public discussion and advisory work surrounding genetic privacy and nondiscrimination before passage of the Genetic Information Nondiscrimination Act of 2008.
- Received the James Tolbert Shipley Prize at Harvard Medical School for published research in 1979.
- Held academic appointments at Harvard, Stanford, UC San Francisco, and UC Berkeley.
- Served in scientific and genomic-medicine advisory roles connected with the FDA, Department of Veterans Affairs, HHS, and the Institute of Medicine.
- Co-founded genomics companies and served as an executive or director across clinical diagnostics, sequencing, and precision-medicine businesses.
- Published extensively across genetics, diagnostics, ethics, public policy, and molecular medicine.

## Latest updates

- **2026-01** — Joined Lindus Health's Scientific Advisory Board to advise on strategy for clinical research and diagnostics.
- **2026-01** — Listed publicly as founder and chief medical officer of Longevity Life Advisors.
- **2025-01** — Appointed consulting chief medical officer of Oncocyte, supporting clinical strategy, regulatory and reimbursement work, business development, and partnerships.
- **2024-07** — Public career records indicate the end of his chairman and CEO tenure at Biological Dynamics.

## Links

- LinkedIn: https://www.linkedin.com/in/paul-billings-md-phd-01573199

---

Profile page: https://yespress.io/paul-billings
Published by YesPress — https://yespress.io
Last updated: 2026-08-11